List of Excipients in Branded Drug ASPIRIN-DIPYRIDAMOLE

Generic Drugs Containing ASPIRIN-DIPYRIDAMOLE

Company	Ingredient	NDC	Excipient
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	ALCOHOL
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	AMMONIA
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	BUTYL ALCOHOL
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	CELLULOSE, MICROCRYSTALLINE
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	D&C YELLOW NO. 10
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	FD&C RED NO. 40
Zydus Pharmaceuticals USA Inc	aspirin-dipyridamole	68382-618	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in ASPIRIN-DIPYRIDAMOLE?

# Of NDCs	Excipient
2	ALCOHOL
2	AMMONIA
2	BUTYL ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10
2	FD&C RED NO. 40
2	FERROSOFERRIC OXIDE

Aspirin-Dipyridamole Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Aspirin-dipyridamole is a mature modified-release antiplatelet product with limited current patent protection and established generic competition. The principal commercial opportunity is not a new active pharmaceutical ingredient. It is the development of bioequivalent multiparticulate formulations, lower-cost manufacturing platforms, region-specific dosage forms, and differentiated products that improve swallowing, stability, adherence, or supply reliability.

The reference product, Aggrenox, combines 25 mg of immediate-release aspirin with 200 mg of extended-release dipyridamole in a twice-daily capsule. Its formulation separates the two active ingredients because aspirin requires rapid release while dipyridamole requires prolonged release. That physical and pharmacokinetic separation creates the main excipient and manufacturing opportunities.

What is the aspirin-dipyridamole reference product?

Aspirin-dipyridamole extended-release capsules are indicated for secondary prevention of stroke and transient ischemic attack in patients who have experienced cerebral ischemia caused by thrombosis. Aggrenox is marketed by Boehringer Ingelheim Pharmaceuticals under U.S. NDA 020884.[1]

Attribute	Reference product
Brand	Aggrenox
Active ingredients	Aspirin 25 mg and dipyridamole 200 mg
Dosage form	Hard gelatin capsule
Aspirin release	Immediate release
Dipyridamole release	Extended release
Dosing	One capsule twice daily
Primary use	Secondary prevention of ischemic stroke
U.S. regulatory pathway	NDA 020884
Generic status	Approved ANDA products are available
Biosimilar exposure	None, because both active ingredients are small molecules

The product is technically more complex than a conventional aspirin capsule. Its performance depends on controlling the release of dipyridamole while preventing aspirin degradation and maintaining uniformity between separate active-containing units.

What excipients are used in aspirin-dipyridamole capsules?

The reference formulation uses excipients for pellet formation, controlled release, moisture management, capsule filling, coating, and product identification. Listed inactive ingredients vary by manufacturer and market, but commercial formulations commonly use the following materials.[1,2]

Functional role	Common excipient classes	Formulation purpose
Pellet or core former	Sugar spheres, microcrystalline cellulose, starch	Provides a substrate for drug layering
Binder	Povidone, hypromellose	Promotes adhesion of active layers
Release-controlling polymer	Methacrylic acid copolymers, ethylcellulose, hypromellose	Controls dipyridamole dissolution
Plasticizer	Triacetin, polyethylene glycol or equivalent	Improves coating flexibility
Anti-tacking agent	Talc, colloidal silicon dioxide	Prevents pellet agglomeration
Opacifier and colorant	Titanium dioxide, iron oxides	Controls capsule or pellet appearance
Capsule shell	Gelatin or hypromellose	Encapsulates separate release populations
Protective excipient	Povidone, starch, moisture-control packaging	Supports physical and chemical stability

The precise commercial formulation should be confirmed against the applicable FDA label and product-specific ANDA records. Generic products may use different inactive ingredients while achieving pharmaceutical equivalence and bioequivalence.

Why aspirin and dipyridamole need separate release systems

Aspirin is intended to be released rapidly. Dipyridamole has poor and variable aqueous solubility and requires a sustained-release design to maintain exposure over the dosing interval. Combining both drugs in a single homogeneous matrix creates a risk that the excipient system optimized for dipyridamole will delay aspirin or that the formulation environment will accelerate aspirin hydrolysis.

The most defensible formulation architecture is therefore a capsule containing:

1. Immediate-release aspirin-containing particles.
2. Extended-release dipyridamole pellets.
3. A capsule shell and fill system that prevents segregation and maintains dose uniformity.

That structure also creates a manufacturing advantage because each release population can be optimized independently before final encapsulation.

What excipient strategy best supports generic aspirin-dipyridamole?

The leading strategy is a multiparticulate platform with independent control of aspirin release and dipyridamole release. This approach offers more control than a single bilayer tablet and can reduce the risk that one active ingredient will alter the release of the other.

Immediate-release aspirin subsystem

The aspirin fraction should prioritize rapid wetting, fast disintegration, low moisture exposure, and chemical stability. Candidate excipients include:

• Microcrystalline cellulose for compactability and structural support.
• Low-substituted hydroxypropyl cellulose or crospovidone for rapid disintegration.
• Starch or pregelatinized starch for disintegration and processability.
• Colloidal silicon dioxide to improve flow.
• Low-moisture binders where wet granulation is used.

A direct-compression or dry-granulation approach can reduce water exposure. Wet processing is commercially feasible but creates a greater risk of aspirin hydrolysis to salicylic acid. Water activity, drying endpoint, residual moisture, and packaging performance should be treated as critical quality attributes.

Extended-release dipyridamole subsystem

The dipyridamole fraction can use drug-layered inert spheres, matrix pellets, coated granules, or multiparticulate beads. Candidate excipient systems include:

• Hypromellose matrices for diffusion-controlled release.
• Ethylcellulose coatings for pH-independent release.
• Methacrylic acid copolymers for pH-responsive or enteric behavior.
• Povidone or hypromellose as drug-layering binders.
• Talc or colloidal silicon dioxide as anti-tacking agents.
• Triacetin or other plasticizers to improve film flexibility.
• Polysorbates or wetting agents where needed to improve dipyridamole dissolution.

Dipyridamole release is sensitive to particle size, coating weight gain, polymer permeability, pore formation, and gastrointestinal pH. A formulation that relies on a narrow coating window may be difficult to manufacture at scale. A robust product should maintain dissolution performance across realistic variation in coating thickness, pellet diameter, and storage humidity.

Capsule-fill system

Capsule filling is a central commercial risk. Immediate-release aspirin particles and extended-release dipyridamole pellets have different densities, particle sizes, and flow characteristics. Segregation can produce content-uniformity failures even when each component is manufactured correctly.

Commercial controls should include:

• Narrow particle-size distributions.
• Separate storage and transfer of each multiparticulate fraction.
• Controlled blending time.
• Low-shear handling.
• Defined bulk density ranges.
• In-process capsule-weight monitoring.
• Blend uniformity testing at startup and after line interruptions.

A capsule design with visually distinct pellet populations may also assist manufacturing inspection and counterfeit detection, although colorants should not be added unless they provide a clear technical or market benefit.

What formulation patents protect aspirin-dipyridamole?

The historic patent value in aspirin-dipyridamole has centered on the combination of immediate-release aspirin with extended-release dipyridamole, rather than on broad ownership of individual excipients. The relevant protection has included composition, dosage form, release profile, and treatment claims associated with the combination product.

Commercially relevant U.S. patent protection for Aggrenox has expired, and approved generic products have entered the market. The FDA Orange Book no longer provides a meaningful unexpired patent barrier that prevents ordinary ANDA competition against the reference product.[3,4]

Protection category	Current commercial position
Core combination product	Historic protection has expired
Dipyridamole extended-release design	Historic protection has expired or is no longer a practical barrier to approved generic entry
Immediate-release aspirin component	No meaningful standalone barrier
Method-of-use claims for stroke prevention	Mature and commercially weak as an exclusivity tool
Excipient selection	Generally unpatentable in isolation unless tied to a new performance result
New formulation platform	Potentially patentable if it shows non-obvious release, stability, or manufacturing advantages
Biosimilar protection	Not applicable

A new patent strategy would need to focus on a concrete technical distinction, such as a novel release profile, improved stability under accelerated conditions, reduced food effect, smaller capsule size, or a manufacturing process that materially improves yield.

When did aspirin-dipyridamole lose exclusivity?

The product has lost its original U.S. market exclusivity and faces generic competition. FDA approved generic aspirin and extended-release dipyridamole capsules, including products from Teva and other manufacturers, through the ANDA pathway.[4,5]

The practical exclusivity timeline is:

Milestone	Commercial effect
Aggrenox U.S. approval in 1999	Established the reference product
Original NDA exclusivity period	Expired
Historic patent term	Expired
Generic ANDA approvals	Opened the market to multisource competition
Current market	Price competition and supply differentiation dominate

A Paragraph IV challenge is therefore primarily a historical issue for this product. New entrants generally do not need to overcome a live branded patent estate to market an ordinary bioequivalent product in the United States.

What is the Orange Book status of aspirin-dipyridamole?

Aspirin-dipyridamole is an Orange Book-listed prescription combination product with approved generic equivalents. The key regulatory status is pharmaceutical equivalence and bioequivalence, not biologic similarity.

The main implications are:

• ANDA applicants can reference the approved NDA product.
• The applicant must demonstrate the required strength, dosage form, route, labeling, quality, and bioequivalence characteristics.
• The applicant must address any listed patents and exclusivities applicable at the time of filing.
• An applicant does not need to repeat the full clinical efficacy program for stroke prevention.
• Excipient differences are acceptable if they do not affect safety, quality, performance, or bioequivalence.

FDA guidance for modified-release products places substantial weight on comparative dissolution and pharmacokinetic performance. A generic product must show that the dipyridamole release profile is sufficiently comparable and that the aspirin component behaves as an immediate-release dose.[6]

What bioequivalence risks are created by excipient selection?

The highest-risk variables are dissolution, food effect, gastric residence, and stability.

Dissolution risk

A small change in polymer grade, viscosity, coating weight, or plasticizer concentration can alter dipyridamole release. A formulation may meet average dissolution targets while failing at individual time points or under multiple pH conditions.

Food-effect risk

High-fat meals can change gastric emptying, pellet dispersion, and drug dissolution. Excipient systems that depend on rapid dispersion or pH-triggered polymer behavior should be tested under fed and fasted conditions.

Aspirin degradation

Aspirin is sensitive to moisture and can hydrolyze to salicylic acid. Hygroscopic excipients, residual water from aqueous coating, and permeable packaging can reduce shelf life.

Capsule rupture and pellet release

Capsule shell moisture affects brittleness, dissolution, and mechanical integrity. Gelatin and hypromellose shells have different moisture-transfer characteristics. This creates a potential opportunity for a moisture-controlled shell or high-barrier packaging configuration.

Dose dumping

A sustained-release dipyridamole system must resist rapid release caused by alcohol, mechanical stress, pH changes, or coating defects. The use of robust film coatings and validated in vitro release testing is central to product approval.

What commercial opportunities exist in aspirin-dipyridamole excipients?

The strongest opportunities are in formulation platforms and manufacturing services rather than in commodity excipient sales.

1. High-barrier generic capsules

A product using a low-moisture formulation, high-barrier blister, or improved bottle-closure system could reduce aspirin degradation and extend shelf life. The commercial value would be highest in humid markets and in distribution systems with weak temperature and humidity control.

2. Smaller or easier-to-swallow dosage forms

Aggrenox is administered twice daily and uses a capsule containing separate release populations. A smaller capsule, sprinkle formulation, or alternative multiparticulate presentation could target patients with dysphagia or swallowing difficulty. Any change would require new bioequivalence and product-performance work.

3. Stable pediatric or geriatric formulations

The approved indication is primarily an adult stroke-prevention use, but age-related swallowing problems create an opportunity for a capsule that can be opened and administered with a suitable vehicle. The key technical issue is maintaining dose uniformity and preventing damage to the extended-release pellets.

4. Excipient substitution

Alternative polymers can reduce cost or improve supply security. Candidates include different grades of hypromellose, ethylcellulose, methacrylate copolymers, and aqueous coating systems. The opportunity is strongest when a supplier can provide equivalent dissolution performance with lower coating weight or fewer process steps.

5. Dual-source manufacturing

The product is well suited to a platform with independently manufactured aspirin and dipyridamole multiparticulates. This allows a manufacturer to qualify more than one source for polymer, sugar spheres, capsule shells, or coating materials without redesigning the entire product.

6. Regional products

Many markets may support locally manufactured aspirin-dipyridamole products where imported branded supply is expensive or inconsistent. Local firms can compete through lower production cost, government tenders, and contract manufacturing. The main barrier is regulatory documentation for modified-release performance.

How strong is the patent estate for aspirin-dipyridamole?

The current patent estate is weak as a barrier to ordinary generic entry but remains relevant for differentiated products.

Asset type	Barrier strength	Commercial assessment
Expired core combination patents	Low	No current exclusionary value
Basic aspirin-dipyridamole composition	Low	Commodity-like
Standard extended-release pellet formulation	Low to moderate	Patentability depends on specific technical features
Novel polymer architecture	Moderate	Potentially defensible with data
Improved moisture-stability system	Moderate	Stronger if linked to measurable shelf-life gains
New dosage form	Moderate	Requires clinical and bioequivalence support
Manufacturing process	Moderate	Useful for trade-secret protection and process patents
Method of use	Low	Mature indication and limited differentiation

A company seeking patent protection should build claims around measurable product attributes rather than generic references to excipient categories. Examples include a defined dissolution range, a specified polymer ratio, a moisture threshold, a stability result, or a manufacturing step that produces a predictable release profile.

Which companies are challenging or competing with Aggrenox?

The relevant competitors are generic manufacturers, not biosimilar developers. Teva obtained approval for generic aspirin and extended-release dipyridamole capsules, and other manufacturers have marketed or pursued equivalent products through the ANDA pathway.[4,5]

Competition is based on:

• Product acquisition cost.
• Supply continuity.
• Pharmacy substitution.
• Government and institutional tender pricing.
• Authorized-distributor coverage.
• Contract manufacturing capacity.
• Stability in global distribution.
• Ability to maintain modified-release specifications at high volume.

Because both active ingredients are established small molecules, biosimilar risk is zero. The risk is conventional generic erosion, with additional competition from aspirin monotherapy, clopidogrel, and other antiplatelet regimens used in secondary stroke prevention.

How does aspirin-dipyridamole compare with competing antiplatelet products?

Product	Release design	Generic competition	Main commercial advantage
Aspirin-dipyridamole ER	Immediate-release aspirin plus extended-release dipyridamole	High	Established combination and twice-daily regimen
Aspirin	Immediate release	Very high	Low cost and broad availability
Clopidogrel	Immediate release tablet	High	Once-daily dosing and simple manufacturing
Aspirin plus clopidogrel	Two immediate-release products	Very high	Flexible dosing, but different clinical use patterns
Extended-release dipyridamole alone	Modified release	High	Single active ingredient and formulation flexibility

Aspirin-dipyridamole can retain commercial value where prescribers prefer the established combination or where clinical guidelines support it for a particular patient population. Its weakness is the more complex formulation and twice-daily dosing compared with once-daily clopidogrel.

What generic launch risks exist for aspirin-dipyridamole?

The principal launch risks are technical, regulatory, and commercial.

1. The dipyridamole dissolution profile may fail under one or more pH conditions.
2. Aspirin degradation may exceed specification during stability testing.
3. Separate particulate populations may segregate during encapsulation.
4. Capsule shell moisture may affect performance.
5. A formulation may demonstrate an unacceptable food effect.
6. The product may be bioequivalent on average but fail variability criteria.
7. Multiple approved generics may compress prices before launch.
8. Hospital and pharmacy buyers may favor established suppliers with reliable allocation.
9. A product may require more coating and testing than its price can support.
10. Changes in excipient supplier or polymer grade may trigger postapproval comparability work.

The best launch candidates combine a low-cost, reproducible coating process with strong moisture protection and a supply chain that supports more than one critical excipient source.

What licensing deals and partnerships are most commercially relevant?

The most realistic partnerships involve:

• Licensed multiparticulate manufacturing technology.
• Contract development and manufacturing for modified-release pellets.
• Regional commercialization rights.
• Excipient supply agreements with qualified alternate sources.
• Packaging partnerships for high-barrier blister systems.
• Co-development of sprinkle or dysphagia-friendly presentations.
• In-licensing of a differentiated formulation with improved stability or reduced capsule size.

A license based only on a routine excipient substitution is unlikely to command significant value. A more credible transaction would include comparative dissolution data, accelerated stability results, scale-up performance, and a clear regulatory pathway.

Key Takeaways

• Aspirin-dipyridamole combines 25 mg immediate-release aspirin with 200 mg extended-release dipyridamole.
• The core formulation opportunity is a two-population multiparticulate system inside one capsule.
• Aspirin protection requires low moisture exposure and controlled water activity.
• Dipyridamole performance depends on polymer selection, coating weight, particle size, and pH-dependent dissolution.
• Aggrenox has lost its original U.S. exclusivity, and generic competition is established.
• Biosimilar risk does not apply because both active ingredients are small molecules.
• New patent value would need to come from a specific formulation, stability, dosage-form, or manufacturing improvement.
• The strongest commercial opportunities are high-barrier packaging, excipient substitution, smaller dosage forms, sprinkle presentations, and regional generic supply.
• Generic launch economics are constrained by formulation complexity and price competition.
• A defensible product should be designed around robust dissolution, low aspirin degradation, minimal segregation, and dual-source excipient supply.

FAQs

Can aspirin-dipyridamole be formulated as one matrix tablet?

Yes, but a single matrix tablet creates a greater risk of delaying aspirin release or disrupting dipyridamole control. Separate immediate-release and extended-release populations generally offer better formulation control.

Which excipient is most important for dipyridamole release?

The release-controlling polymer system is the most important variable. Polymer type, viscosity grade, coating thickness, pore structure, and plasticizer level jointly determine release behavior.

Is an enteric-coated aspirin-dipyridamole product commercially attractive?

It may be technically attractive for reducing gastric aspirin exposure, but it would not be a routine substitute for the reference product. The altered aspirin release profile could require a new regulatory and clinical justification.

Can a manufacturer use different excipients from Aggrenox?

Yes. Generic manufacturers may use different inactive ingredients if the product meets applicable quality, safety, pharmaceutical equivalence, dissolution, and bioequivalence requirements.

What is the most valuable patent angle for a new aspirin-dipyridamole product?

The strongest angle is a demonstrated improvement in a measurable technical attribute, such as moisture stability, reduced food effect, smaller capsule size, controlled multiparticulate release, or improved manufacturing yield.

References

1. Boehringer Ingelheim Pharmaceuticals, Inc. (2023). Aggrenox prescribing information. U.S. Food and Drug Administration.

2. National Library of Medicine. (2024). Aggrenox: Aspirin and extended-release dipyridamole capsule labeling. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2015). FDA approves first generic versions of Aggrenox. FDA Drug Safety and Availability.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: Aggrenox, NDA 020884, and associated abbreviated new drug applications. FDA.

6. U.S. Food and Drug Administration. (2019). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.